Nanotechnology Now - Press Release: Techulon Expands Coverage in Northern Virginia/Maryland Biotech Corridor: Local Sales and Technical Support for Glycofect™ Reagents to Government and University Laboratories

Home > Press > Techulon Expands Coverage in Northern Virginia/Maryland Biotech Corridor: Local Sales and Technical Support for Glycofect™ Reagents to Government and University Laboratories

Abstract:
Techulon Inc., the leader in low-toxicity gene delivery has announced a series of expansions to provide enhanced customer support and direct access to the Company's innovative Glycofect transfection reagent in the Northern Virginia/Maryland Technology Corridor. The Company is dedicated to providing compelling technology for the most challenging DNA delivery needs in key research regions where demand for Glycofect and knowledgeable support are required.

Techulon Expands Coverage in Northern Virginia/Maryland Biotech Corridor: Local Sales and Technical Support for Glycofect™ Reagents to Government and University Laboratories

Blacksburg, VA | Posted on October 6th, 2011

Techulon is pleased Mr. Bill McKay of Olney Biosciences has joined our efforts to provide key account professional services in the Mid-Atlantic region. Mr. McKay will coordinate activities and directly serve clients such as the National Institutes of Health, the National Cancer Institute, and John Hopkins University. "Serving the critical research of NIH and related firms across this biotech community is a privilege and I'm pleased to be working with Techulon to deliver such a quality product," said Bill McKay.

Providing educational information about the Glycofect platform will be the central focus driving Techulon events through the next several months. Techulon is establishing a regular series of seminars and events to provide guidance and training for cell researchers as they begin expanded use of Glycofect in highly critical research programs including Glioma and cortical neurons, dermal fibroblasts and aortic smooth muscle cells. Techulon will roll out its educational initiatives as a focal participant at the October NIH Research Festival at the Institute's main Bethesda campus, and continue to present frequent luncheon workshops throughout 2012. Research team leaders interested in hosting an event should contact Mr. McKay at

"We are gratified that Glycofect is enabling and accelerating research on critical primary cell types and we want to show our commitment to our growing customer base in this important region. Customer awareness and support are top priorities for us as we see the increased use of Glycofect among the research community," said Frank Akers, President of Techulon.

Glycofect is a polymeric nanoparticle-delivery transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used in over 20 countries by government, university and corporate laboratories for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.

####

About Techulon Inc.
Techulon, Inc. is a life sciences company headquartered in Blacksburg, VA, with a core capability in novel biodegradable and low toxicity DNA and RNA delivery reagents for cell-based research and therapeutics.

For more information, please click here

Contacts:
Techulon
Frank Akers, President
540-443-9254

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: